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RESEARCH ARTICLE

Open Access

Explaining the increase in coronary heart disease
mortality in Syria between 1996 and 2006
Samer Rastam1,5*, Radwan AL Ali1, Wasim Maziak1,2, Fawaz Mzayek1,3, Fouad M Fouad1, Martin O'Flaherty4 and
Simon Capewell4

Abstract
Background: Despite advances made in treating coronary heart disease (CHD), mortality due to CHD in Syria has
been increasing for the past two decades. This study aims to assess CHD mortality trends in Syria between 1996
and 2006 and to investigate the main factors associated with them.
Methods: The IMPACT model was used to analyze CHD mortality trends in Syria based on numbers of CHD
patients, utilization of specific treatments, trends in major cardiovascular risk factors in apparently healthy persons
and CHD patients. Data sources for the IMPACT model included official statistics, published and unpublished
surveys, data from neighboring countries, expert opinions, and randomized trials and meta-analyses.
Results: Between 1996 and 2006, CHD mortality rate in Syria increased by 64%, which translates into 6370 excess
CHD deaths in 2006 as compared to the number expected had the 1996 baseline rate held constant. Using the
IMPACT model, it was estimated that increases in cardiovascular risk factors could explain approximately 5140 (81%)
of the CHD deaths, while some 2145 deaths were prevented or postponed by medical and surgical treatments for
CHD.
Conclusion: Most of the recent increase in CHD mortality in Syria is attributable to increases in major
cardiovascular risk factors. Treatments for CHD were able to prevent about a quarter of excess CHD deaths, despite
suboptimal implementation. These findings stress the importance of population-based primary prevention
strategies targeting major risk factors for CHD, as well as policies aimed at improving access and adherence to
modern treatments of CHD.
Keywords: Coronary heart disease, Mortality, Modelling

Background
Coronary heart disease (CHD) is projected to be the
leading global cause of death and disability by 2020 [1].
Most of the global burden from cardiovascular disease
(CVD) morbidity and mortality is taking place in the
developing countries, and CVD has already overtaken
infectious diseases as the main threat to public health
[2-5]. In the Eastern Mediterranean Region (EMR), CVD
mortality accounts for almost a third of all deaths, and is
mainly due to CHD [2]. According to available evidence,
mortality rates from CHD are on the rise for most countries of the EMR [6,7]. In Syria, one of the low-middle
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income countries of the EMR (population  20 million;
2006), CHD is the main cause of CVD mortality, and together with stroke accounts for about half of all-cause
mortality [8]. One of the notable patterns of CHD morbidity and mortality in the EMR compared to developed
countries is their earlier onset, which translates into loss
of productive years and more strain on the already burdened livelihood of poor communities [9].
Designing effective interventions to reduce CHD burden in developing countries needs to be guided by local
data to identify main risk factors driving CHD incidence,
and the most effective approach to reduce CHD burden
considering the resources available [10]. Unfortunately,
for most of the developing world, including countries of
the EMR, very few reliable data exist about the main drivers of CHD mortality in terms of treatment and risk
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factors. As part of a new project funded by the EU
(Medchamps: Mediterranean Studies of Cardiovascular
disease and Hyperglycaemia: Analytical Modelling of
Population Socio-economic transitions), we started collecting and analysing such data for several countries in
the Mediterranean region (Syria, Tunisia, Palestinian authority, and Turkey).
According to WHO estimates, CHD mortality in Syria
showed increasing trends during the past two decades
[11,12]. This study aims to explain these trends between
1996 and 2006, and to examine factors associated with
them, using a validated modelling approach.

Methods
The IMPACT mortality model was adopted in this study
to quantify the effects on CHD mortality attributable to
changes in each population risk factors and treatment
modalities between 1996 and 2006. The IMPACT model
was previously validated in developed and developing
countries such as New Zealand, China and Scotland [1315]. Briefly, the IMPACT model is used to estimate the
number of coronary heart disease (CHD) deaths prevented by each specific cardiac intervention, or risk factor decline or vice versa. The comparison between the
increase of treatment for CHD disease and cardiovascular mortality represents another approach applied to obtain a more precise estimate of the role of the reduction
of each risk factor. In this study, adults’ data including:
(1) number of CHD patients, (2) use of specific medical
and surgical treatments, (3) effectiveness of specific
treatments for CHD, (4) population trends of major cardiovascular risk factors (smoking, total cholesterol,
hypertension, obesity, and diabetes), were incorporated
in the model. Details are shown in Additional file 1.
Data sources and assessment

Syrian data on risk factors and current practices for
treating CHD patients were identified through extensive
search of published and unpublished data and complemented with specifically designed surveys. All data
sources were critically appraised by Syrian Centre for
Tobacco Studies (SCTS) and Medchamps teams and the
results of this process are presented in the Additional
file 1.
Data used to populate the model included: a) population statistics and CHD related mortality, b) patient
numbers in specific CHD groups (Myocardial Infarction
(MI), Congestive Heart Failure (CHF), Chronic Angina
Pectoris (AP), c) use of specific medical and surgical
treatments for CHD, and d) population trends in major
cardiovascular risk factors. The main outcome of the
model was number of deaths prevented or postponed
(DPP) due to changes in risk factors or the application
of certain treatments.
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Information on the population demographic changes

Demographic information for Syria between 1996–2006
were obtained from the Syrian bureau of Statistics [16].
Numbers were comparable to the numbers provided by
the U.N. department of economics and social affairs
[17]. Numbers of CHD related deaths for both years
were obtained from the WHO Global Health Observatory [11]. These numbers were cross-validated with data
provided by the Aleppo Household Survey (AHS), which
was conducted in 2004, and in which mortality estimates
were calculated from participant-reported deaths among
their adult household members (>20 years) during the
five years preceding the time of the survey. [18]. Because
mortality data for Syria are not available for every year,
mortality rates for 1996 were estimated from data of
1985 and 2004, which are the closest available data
points to 1996 using the geometric mean of the agespecific death rates [19]. These data were obtained from
the WHO Statistical Information System [11,12].
Data on population risk factors’ trends

Data for the year 2006 were obtained from two epidemiological studies. The first one was the STEPwise survey –
conducted by WHO in the rural and urban areas of Syria
in 2003 with people up to 65 years were included; and in
which a nationally representative sample of 9184 participants were surveyed [20]. The second one was the Aleppo
Diabetes Survey (ADS) – conducted in 2006 –in which a
representative sample of 1168 aged ≥ 25 years from the
city of Aleppo (2nd largest city with population  2.5 million) were surveyed [21]. Syrian data for the year 1996
were not available; therefore, they were extrapolated from
the Palestinian Authority data, because those data were
the most complete and standardized ones among neighbouring countries and because of the ethnic and cultural
similarities of the two populations.
Data on CHD hospital admissions and (in-hospital)
treatment

Because no valid information was available on CHD
hospitalization and treatment, the SCTS has conducted
a survey in 2009 specifically for this project. The survey
covered 6 major hospitals. Three of these hospitals provide cardiac care in the Aleppo province, and the other
3 were general hospitals.
Data on treatment use for CHD in the community

Data for 2008 were obtained from an outpatient survey
conducted by SCTS in 2009 using a random sample of
five health centres. Information on treatment uptake in
the community was verified with the help of experts’
opinion using a special questionnaire about treatment of
CHD, assuming that treatment use did not change significantly between 2006 and 2008.
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Data on efficacy of therapeutic interventions

Data were based on the results of recent meta-analyses
and randomised controlled trials [22-52]. The Mant and
Hicks approach was used to correct for polypharmacy in
individual patients [53].
Population and mortality data were obtained from
openly available sources; data on current risk factor profile and treatment uptakes were obtained from surveys
conducted by SCTS; while data on risk factor profile for
1996 with permission to be used was obtained with from
Institute of Community and Public Health, Birzeit
University.
Assessment of trends in CHD deaths (1996–2006) and the
relative contribution of treatment and risk factors

First, the number of CHD deaths expected in 2006 was
calculated by indirect age standardisation based on the
assumption that 1996 mortality rates had persisted unchanged until 2006. The number of CHD deaths actually
observed in 2006 was then subtracted. The difference between the two represents the rise in CHD deaths that
the model needed to explain.
The number of additional deaths attributable to
changes in cardiovascular risk factors was estimated
using regression coefficients (β) to quantify the population mortality impact of changes in risk factors measured as continuous variables (blood pressure, total
cholesterol and BMI). For categorical risk factors, including diabetes, physical inactivity and smoking, the
population attributable risk fraction was used based on
the standard formula:
PAR ¼

Prevalence 0:5emxðRelative Risk  1Þ
½Prevalence xðRelative Risk  1Þ þ 1

To assess the effect of the treatment type on CHD
mortality, the model needed to include all medical and
surgical treatments in 1996 (the base year) and 2006
(the final year). However, detailed information on treatment modalities was not available for the year 1996. The
data included in the model for 1996 were therefore estimated based on feedback from the ten leading local cardiologists in Aleppo, who treated CHD patients in
hospitals and the community at that time using a short
survey with standardized questions commonly used in
the IMPACT model.
The mortality reduction attributable to each treatment
type was calculated as the number of patients in each age
and sex group multiplied by three factors: 1) the baseline,
age-specific case fatality rate observed in that group, 2)
the relative mortality reduction reported in published
meta-analyses [22-52], and 3) the proportion receiving
that specific treatment (Additional file 1). Case-fatality
data were obtained from large, unselected, population-
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based patient cohorts [54]. Survival benefit over a oneyear time interval was used for all treatments.
Potential overlaps between different groups of patients
were identified and appropriate adjustments were made.
Patient group calculations and all other assumptions are
detailed in the Additional file 1. Adherence (defined as
the proportion of treated patients actually taking therapeutically effective levels of the prescribed medication)
was assumed to be 100% among hospital patients, 70%
among all symptomatic community patients, and 50%
among asymptomatic community patients, based on the
literature. [55-57]
Sensitivity analysis

Because of the uncertainties surrounding some of the
values used in the modelling, multi-way sensitivity analysis using Brigg’s analysis of extremes was used. [58]

Results
Between 1996 and 2006, CHD mortality rates in Syria
increased by 64% (from 129 to 212 per 100,000 personyears; 58% in men and 75% in women). This resulted in
6370 additional CHD deaths in 2006 compared to the
number expected had the 1996 mortality rates persisted.
Mortality increases were seen in men and women in all
age groups (Table 1).
Major CHD risk factors

Of the 6370 excess CHD deaths in 2006, 5140 (minimum 3165 and maximum 7705) can be explained by
changes of major cardiovascular risk factors between
1996 and 2006. This represents 80.7% of the observed
increase in CHD- mortality.
Changes in risk factors were complex: 0.31 mmol/L
rise in total cholesterol (0.22 mmol/L in men and 0.39
mmol/L in women), 9 mmHg rise in mean systolic blood
pressure (SBP) (6 mmHg in men and 11 mmHg in
women), 4.7% rise in diabetes prevalence (4.1% in men,
5.3% in women), and a 1.8 units rise in BMI (1.5 in men,
2.2 in women).
Approximately 52% (2680, minimum 1620 and maximum 4110) of the excess deaths that were explained by
changes in cardiovascular risk factors were attributable
to increases in SBP; 19% (1000, 640 and 1460) to
increases in total cholesterol; 15% (770, 490 and 1105)
to increases in diabetes prevalence; 9% (470, 270 and
710) to increases in BMI; and 4% (225, 145 and 320) to
increases in smoking prevalence. (Table 2).
Medical and surgical treatments

Medical and surgical treatments together prevented or
postponed approximately 2145 deaths in 2006 (minimum 1135, maximum 5475). In the absence of these
treatments, there would have been approximately 2145
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Table 1 Population sizes and death rates from CHD in Syria, 1996 and 2006
Men
Age groups

25-34

35-44

45-54

55-64

65-74

+75

+25

Population in 1996

1063649

652453

381580

269255

171321

62074

2600332

Population in 2006

1478983

1053893

636889

351702

213778

107432

3842677

Deaths in 1996 (number)

379

542

522

743

1423

583

4191

Deaths in 2006 (number)

955

1573

1263

1327

3000

1674

9793

Death rates per 100,000 in 1996

36

83

137

276

831

939

161

Death rates per 100,000 in 2006

65

149

198

377

1403

1558

255

81%

80%

45%

37%

69%

66%

58%

+75

+25

% Change (crude)

Women
Age groups

25-34

35-44

45-54

55-64

65-74

Population in 1996

1019177

634984

381124

271637

168367

66709

2541998

Population in 2006

1432147

1016763

627629

363840

234341

127094

3801814

Deaths in 1996 (number)

145

195

256

314

911

642

2463

Deaths in 2006 (number)

315

517

680

604

2268

2061

6445

Death rates per 100,000 in 1996

14

31

67

116

541

963

97

Death rates per 100,000 in 2006

22

51

108

166

968

1622

170

55%

66%

61%

44%

79%

68%

75%

% Change (crude)

additional CHD deaths. The total treatment effect represented a 34% reduction of the overall CHD mortality
(minimum estimate 18% and maximum 86%, Figure 1).
Treatment of angina pectoris in the community
explained over 38% of reduction in CHD deaths (805,
minimum 665 and maximum 2125), most being attributable to aspirin and statin therapies (Table 3).
Secondary prevention following acute myocardial infarction explained over 17% of reduction in CHD deaths
(370), mostly due to beta blockers and aspirin). Approximately 15% (330) of deaths were prevented by
heart failure treatments in the community (particularly
spironolactone), and 14% (290) were attributable to initial treatments for acute myocardial infarction (especially thrombolysis and aspirin). However, the mortality
reductions attributable to coronary surgery and statins
for primary prevention were modest (4.7% and 2.3% respectively, Table 3).
Model validation and fit

The model explained approximately 81% of the total
CHD mortality increase in the Syrian population between 1996 and 2006. The remaining 19% was unexplained and might reflect data limitations or other
unmeasured factors such as physical inactivity, stress
dietary factors.
It is perfectly reasonable to instead present the total
deaths to explain as 8,515 deaths (6,370 + 2,145) deaths.
In which case the 5140 deaths attributable to risk factor
changes would represent approximately 60% of the total
mortality increase.

The relative contributions of the risk factors studied
remained relatively consistent, irrespective of whether
the best, the minimum, or the maximum DPP estimates
were used.

Discussion
Coronary heart disease mortality increased in Syria by
over 60% between 1996 and 2006. These trends
resembled those in other developing countries such as
China (using the same IMPACT model), as well as India
[14,59]. Much of this mortality rise can be attributed to
adverse trends in major risk factors such as blood pressure, cholesterol and diabetes. This is the first study to
examine factors underlying the rise of CHD mortality in
Syria. It, therefore, provides important and timely information that could guide national efforts to reduce the
burden of CHD in Syria. It also can potentially provide
useful information for other comparable Arab countries
in the EMR.
The largest fractions of CHD excess mortality paralleled the increases in major CHD risk factors, with almost 60% of the mortality increase being attributable to
elevated blood pressure and total cholesterol. These
trends are consistent with the overall shift in Arab societies towards urbanization, modernization and lifestyles
characterized by unhealthy diet and inactivity. Available
data from Syria and other Arab countries in the EMR
consistently show dramatic increases in obesity and diabetes, whereby overweight and obesity among adults in
the EMR range from 25% to a staggering 82% [60]. In
Syria obesity now affects over half (52%) of adult women
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Table 2 Deaths attributable to population risk factor changes in Syria between 1996 and 2006
RISK FACTORS*

Risk factor levels
1996 2006

Relative
Change (%) in risk
factor 1996-2006

Relative Risk (RR1)
(or βeta Coefficient)2

Cholesterol mmol/l
Cholesterol (men)

5.01

5.23

4.5

β 0.65

Cholesterol (women)

5.07

5.46

7.6

β 0.65

Smoking ( % )

1,60 (1–9 cig/d);

Increase in Deaths
Best
Estimate

Minimum
estimate

Maximum
estimate

Proportion of
overall deaths

1000

635

1460

15.7%

225

145

320

3.5%

470

270

710

7.3%

770

490

1105

12.0%

2680

1620

4110

42.1%

1.80 (10–19 cig/d);
2.10 (>20 cig/d)
(% men smoking)

55.3

58.6

6.0

(% women smoking)

10.0

15.0

49.4

BMI Kg/m2
BMI (men)

26.75

28.26

5.6

β 0.02

BMI (women)

29.08

31.24

7.4

β 0.02

Diabetes (men)

7.4

11.5

55.6

2

Diabetes (women)

10.1

15.5

52.6

2

Diabetes (%)

Population systolic BP mm/Hg
Population BP (men)

125.6

131.8

4.9

β 0.053

Population BP (women)

118.7

129.9

9.5

β 0.053

-

-

-

-

Physical inactivity

Estimated total risk factor effects
*

-

-

-

-

5140

3155

7705

80.7%

Numbers of increases in deaths were rounded to nearest 0 or 5.

[21]. These unfavourable trends contribute to an adverse
cardiovascular risk factors’ profile, including a higher
prevalence of diabetes and elevated cholesterol levels, as
is seen in this study. The common behavioural roots
underlying CVD risk increases in the Syrian population
potentially highlight opportunities to reduce mortality
rates through population–based interventions promoting
healthy eating and active lifestyles. This also emphasizes
the need for a national strategy to address noncommunicable diseases in Syria using a combination of
health promotion, fiscal measures, market controls and
community involvement to encourage healthy lifestyles
[61]. The contribution of smoking to increased CHD
mortality was modest, as smoking prevalence hardly
changed between 1996 and 2006.
This reflects a lack of effective tobacco control policies
in Syria, and a complex political situation, where the
government agency responsible for tobacco production
and sale is much more powerful that the tobacco control
unit at the ministry of health.
Modern medical treatments together prevented or
postponed 2145 excess deaths in Syria in 2006, equivalent to about one fourth of the total CHD mortality. The
biggest contributions came from long-term management

of CHD, mainly for secondary prevention, angina, and
heart failure. The contributions from surgery and angioplasty were small, accounting for 4% of the mortality reduction. Our previous research in Syria showed that in
spite of high prevalence of CHD risk factors, such as
hypertension, awareness and, consequently, treatment
and control of such conditions tended to be low [21].
For example, our research has shown that about 40.6%
of population aged 18–65 years had hypertension, only
11.8% of them were aware of it, and only 8.6% were
under treatment [8]. For diabetes, which affects 15.6% of
population aged 25 years and above in Syria, only 11.2%
were diagnosed, and only 16.7% of treated cases had
their diabetes controlled adequately [62]. This modest
contribution of medical treatment to reducing CHD
mortality points out to a great potential for improvement in this area.
Treatment uptakes were moderate (60%-90%) for relatively cheap drugs, such as aspirin, thrombolytic therapy,
and beta blockers, but much lower for more expensive
surgical procedures. There was essentially no utilization
of coronary artery bypass graft (CABG), primary transcutaneous coronary angioplasty (PTCA), rehabilitation,
nor cardiac pulmonary resuscitation (CPR) in the
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Figure 1 Coronary heart disease deaths prevented or postponed by treatment and risk factors changes in the Syrian population
between 1996 and 2006.

community. In our study, surgical procedures had a very
limited role in avoiding CHD deaths, resulting in approximately 100 fewer deaths ( 5% of total treatment
benefit). This small role may reflect the effects of the
high cost of these procedures, the lack of access to specialized care for the general population, the limited availability of expertise and facilities needed to perform such
procedures and the underdevelopment of the private
and public health insurance sectors--a situation similar
to that found in other developing countries, such as
China [14]. This contrasts with the higher uptake in
developed countries where, for instance, community resuscitation (i.e. out of health care facilities) reached 48%
in England and Wales [63], and 50% in New Zealand
[13].
The IMPACT modelling in this study used a comprehensive approach, synthesizing data about all major risk
factors and all standard treatment options used in the
Syrian population between 1996 and 2006. However, this
approach also has some limitations. The data used were
of variable completeness and quality. We critically
appraised the available data to ensure adequate quality
for our modeling. For example, we did not rely on national death registry data for causes of death because
these were incomplete and of questionable quality, instead, preferring mortality data from WHO estimates
[11,12]. In addition, when data were not available, we
used explicit assumptions including data from a comparable neighboring (Palestinian) population.
It is also perfectly reasonable to present the total
deaths to explain as 8,515 deaths (6,370 + 2,145). In

which case the 5140 deaths attributable to risk factor
changes would represent approximately 60% of the total
mortality increase.
Lag times were not formally considered in the model.
However, increasing evidence suggests that substantial
mortality increases or falls may occur within a few years
of risk factor changes [64]. Furthermore, certain assumptions were needed to fill in the gaps for missing information. For example, for the small group aged 65–74 years
where risk factor information was not available we had
to make assumptions based on the risk factors levels in
the nearest age groups. These assumptions are detailed
in the Additional file 1 and were supported by local expert opinions and literature from the region. All were
tested in the sensitivity analysis. However, none of these
limitations are expected to influence the validity of our
main results, as the IMPACT model used in this study
was developed to deal with such data problems.

Conclusions
CHD mortality in Syria rose by about 60% between 1996
and 2006. More than two-thirds of this rise was attributable to changes in major risk factors such as blood pressure and total cholesterol. Despite suboptimal use, CHD
treatments prevented or delayed 2145 CHD deaths in
2006 compared to 1996. These results emphasise the importance of advocating adequate, early, and continuous
treatments for CHD within the community.
Risk factor changes in the general population are important drivers of the recent CHD mortality rises, and
mainly reflect lifestyles characterised by unhealthy eating
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Table 3 Deaths prevented or postponed by medical and surgical treatments in Syria in 2006
TREATMENTS

Acute myocardial infarction

Patients
eligible

Treatment
uptake (%)

18002

CHD deaths prevented or postponed

Proportion of overall deaths

Best
Estimate

Minimum
estimate

Maximum
estimate

Prevented or
postponed (%)

285

120

540

4.5%

Hospital resuscitation

0.05

13

8

23

0.2%

Aspirin alone

0.96

151

62

266

2.4%

Thrombolytic alone

0.59

128

53

266

2.0%

Beta blockers

0.82

29

12

59

0.5%

ACE inhibitors

0.74

56

23

115

0.9%

−92

−37

−191

372

125

949

5.8%

0.46

112

37

278

1.8%

Beta blockers

0.47

125

41

310

2.0%

ACE inhibitors

0.33

92

30

230

1.4%

Statins

0.28

90

29

223

1.4%

Warfarin

0.04

16

5

39

0.2%

Rehabilitation

0.10

0.6%

Treatments in 1996 subtracted
Secondary Prevention
post infarction

78976

Aspirin

Treatments in 1996 subtracted
Secondary Prevention post
revascularisation (5 years)

106517

Angina

36

12

89

−97

−29

−219

65

22

164

1.0%

803

664

2124

12.6%

CABG surgery (1997–2006)

106517

0.10

97

-

-

1.5%

Aspirin

319974

0.44

511

168

1273

8.0%

Statins

319974

0.34

6.9%

Treatments in 1996 subtracted

443

116

1322

−248

−75

−671

Treatments for unstable angina

22877

150

92

403

2.3%

Heart Failure with Hospital
admission

6927

84

25

223

1.3%

41

11

122

0.6%

ACE inhibitors

0.57

Beta blockers

0.22

22

6

67

0.4%

Spironolactone

0.49

64

21

160

1.0%

Aspirin

0.80

0.9%

Treatments in 1996 subtracted
Heart failure in the community

52251

55

18

135

−99

−30

−262

332

104

854

5.2%

ACE inhibitors

112

29

327

1.8%

Beta blockers

108

35

269

1.7%

Spironolactone

226

74

563

3.6%
1.5%

Aspirin
Treatments in 1996 subtracted

97

32

240

−211

−66

−546

Hypertension Treatments

863425

45

8

311

0.7%

Statins for Primary Prevention

307295

6

2

65

0.5%

2145

1165

5630

33.7%

Total treatment effects*

* Numbers of category totals of deaths prevented or postponed were rounded to nearest 0 or 5, totals may therefore not always sum exactly.
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft surgery.
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habits and physical inactivity. These should be the priority
targets for national efforts to reduce cardiovascular morbidity and mortality. This will represent great challenges,
because effective, population-based policies will require
clear public health vision, multi-sectoral approaches, adequate resources and firm political commitment [64].
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Model; Data Sources Assumptions and Risks.
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